AZN Jan 2026 32.500 call
| Previous Close | 39.20 |
| Open | 35.05 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 32.50 |
| Expire Date | 2026-01-16 |
| Day's Range | 35.05 - 39.20 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
ZacksAZN Gets FDA Nod for Fasenra Label Expansion in Rare Disease
The FDA okays AstraZeneca's Fasenra for treating adults with eosinophilic granulomatosis with polyangiitis. This is the second approved indication for the drug.
Business WireFASENRA approved in the US for eosinophilic granulomatosis with polyangiitis
WILMINGTON, Del., September 18, 2024--AstraZeneca’s FASENRA® (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).1 EGPA is a rare, immune-mediated vasculitis that can result in damage to multiple organs, and without treatment, can be fatal.2,3
GlobeNewswireInternational companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024
NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Tuesday, September 24 and Wednesday, September 25, featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the US. Representatives from participating companies based in China, France, Hong Kong, Netherlands, Philippines, Portugal, Spain, Switzerland, and the United Kingdom will respo
